141 related articles for article (PubMed ID: 33355909)
1. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
Yamaguchi K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Omuro Y; Tamura T; Piao Y; Homma G; Jen MH; Liepa AM; Muro K
Clin Drug Investig; 2021 Jan; 41(1):53-64. PubMed ID: 33355909
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
Al-Batran SE; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov ON; Kim TY; Cunningham D; Rougier P; Muro K; Liepa AM; Chandrawansa K; Emig M; Ohtsu A; Wilke H
Ann Oncol; 2016 Apr; 27(4):673-9. PubMed ID: 26747859
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
5. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
Cascinu S; Bodoky G; Muro K; Van Cutsem E; Oh SC; Folprecht G; Ananda S; Girotto G; Wainberg ZA; Miron MLL; Ajani J; Wei R; Liepa AM; Carlesi R; Emig M; Ohtsu A
Oncologist; 2021 Mar; 26(3):e414-e424. PubMed ID: 33274542
[TBL] [Abstract][Full Text] [Related]
6. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Shitara K; Muro K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Yamaguchi K; Segawa Y; Omuro Y; Tamura T; Doi T; Yukisawa S; Yasui H; Nagashima F; Gotoh M; Esaki T; Emig M; Chandrawansa K; Liepa AM; Wilke H; Ichimiya Y; Ohtsu A
Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
8. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
Chau I; Fuchs CS; Ohtsu A; Barzi A; Liepa AM; Cui ZL; Hsu Y; Al-Batran SE
Eur J Cancer; 2019 Jan; 107():115-123. PubMed ID: 30557792
[TBL] [Abstract][Full Text] [Related]
9. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
[TBL] [Abstract][Full Text] [Related]
10. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
[TBL] [Abstract][Full Text] [Related]
11. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
Muro K; Oh SC; Shimada Y; Lee KW; Yen CJ; Chao Y; Cho JY; Cheng R; Carlesi R; Chandrawansa K; Orlando M; Ohtsu A
J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.
De Vita F; Borg C; Farina G; Geva R; Carton I; Cuku H; Wei R; Muro K
Future Oncol; 2019 Aug; 15(23):2723-2731. PubMed ID: 31234645
[No Abstract] [Full Text] [Related]
15. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer.
Iwai M; Ito D; Asano H; Adachi S; Okada K; Kimura M; Usami E; Matsuo K; Yoshimura T; Teramachi H
Pharmazie; 2018 May; 73(5):309-312. PubMed ID: 29724300
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
Cescon DW; Schmid P; Rugo HS; Im SA; Md Yusof M; Gallardo C; Lipatov O; Barrios CH; Perez-Garcia J; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Haiderali A; Zhou X; Guo Z; Nguyen AM; Cortes J
J Natl Cancer Inst; 2024 May; 116(5):717-727. PubMed ID: 38070159
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
[TBL] [Abstract][Full Text] [Related]
19. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.
Boisteau E; François E; Aparicio T; Le Malicot K; Boulahssass R; Lecomte T; Laurent-Puig P; Guiu B; Paillaud E; Galais MP; Lopez-Trabada Ataz D; Tougeron D; Dourthe LM; Guimbaud R; Samalin E; Moreau M; Louvet C; Lepage C; Lièvre A
Dig Liver Dis; 2022 Jun; 54(6):747-754. PubMed ID: 35351371
[TBL] [Abstract][Full Text] [Related]
20. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Kim TY; Yen CJ; Al-Batran SE; Ferry D; Gao L; Hsu Y; Cheng R; Orlando M; Ohtsu A
Gastric Cancer; 2018 Mar; 21(2):276-284. PubMed ID: 28634748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
